GlassScriptPhysician profile
Edward Ralph Prins
NPI 1619978905
$4,018.00
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,198 · 2020: $557 · 2021: $58.64 · 2023: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $447.68 | 2019-2020 | |
| Allergan, INC. | $368.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $338.77 | 2019 | |
| Amarin Pharma, INC. | $328.35 | 2019-2020 | |
| Radius Health, INC. | $285.41 | 2019-2020 | |
| Amgen INC. | $241.25 | 2019-2020 | |
| Lilly USA, LLC | $216.11 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.42 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $196.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $176.92 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $149.36 | 2019 | |
| Abbvie INC. | $125.00 | 2023 | |
| Pfizer INC. | $113.49 | 2019-2020 | |
| Glaxosmithkline, LLC. | $106.66 | 2019-2023 | Arexvy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $99.58 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $58.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $55.90 | 2019 | |
| Astellas Pharma US INC | $38.73 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $27.85 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.99 | 2020 | |
| Zyla Life Sciences, INC. | $13.76 | 2019 | |
| Shire North American Group INC | $12.61 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.43 | 2019 | |
| Ironwood Pharmaceuticals, INC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Prins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.